In general, children and adolescents are more sensitive than adults to EPS associated with FGAs and SGAs (Correll et al. 2006). An RCT of 40 youth with psychotic disorders comparing haloperidol (mean dosage: 5 mg/day), risperidone (mean dosage: 4 mg/day), and olanzapine (mean dosage: 12 mg/day) found substantial EPS not only with haloperidol (67%) but also with olanzapine (56%) and risperidone (53%), although haloperidol-treated patients reported more severe EPS (Sikich et al. 2004). In another study of 119 pediatric patients with schizophrenia, molindone (mean dosage: 60 mg/day) was associated with greater benztropine use (48%) compared to risperidone (37%, mean dosage: 2.8 mg) and olanzapine (26%, mean dosage: 11 mg/day), even though patients randomly assigned to molindone received 0.5 mg benztropine bid prophylactically (Sikich et al. 2008). Clozapine and quetiapine appear to be associated with relatively low rates of EPS in pediatric patients (as in adults). For aripiprazole and ziprasidone, rates of EPS appear to increase with increasing dose.